SCHEMBL10249224

SCHEMBL10249224

CCc1cnccc1-c1nc2cc(C)cnc2n1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 4/20 0.40
PADI4 Q9UM07 1/20 0.39
AKT1 P31749 3/20 0.37
AKT2 P31751 2/20 0.37
BRD4 O60885 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
POLB P06746 1/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
RPS6KA5 O75582 3/20 0.34
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL116162 0.84 POLB (0.47) PDE10APADI4POLBALDH1A1GRIN1
SCHEMBL10249255 0.84 POLB (0.38) PDE10APADI4AKT1AKT2BRD4
SCHEMBL4403186 0.84 PDE10A (0.40) PDE10AAKT1AKT2BRD4SMN1; SMN2
SCHEMBL10249250 0.83 PDE10A (0.38) PDE10AAKT1AKT2BRD4SMN1; SMN2
SCHEMBL10249089 0.82 POLB (0.40) PDE10AAKT1AKT2SMN1; SMN2POLB
SCHEMBL10248996 0.82 PDE10A (0.40) PDE10AAKT1AKT2BRD4SMN1; SMN2
SCHEMBL4399161 0.82 POLB (0.38) PDE10AAKT1AKT2BRD4SMN1; SMN2
SCHEMBL10248903 0.82 POLB (0.38) PDE10AAKT1AKT2SMN1; SMN2POLB
SCHEMBL10249307 0.82 PDE10A (0.38) PDE10AAKT1AKT2BRD4SMN1; SMN2
SCHEMBL10248971 0.81 PDE10A (0.36) PDE10AAKT1AKT2BRD4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 PDE10A 4112/4885PADI4 2834/4885AKT1 1153/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 PDE10A 4112/4885PADI4 2834/4885AKT1 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.